Rivastigmine in Chinese patients with subcortical vascular dementia

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 943-948

  Mok, Vincent ^a   Wong, Adrian ^a   Ho, Simon ^a   Leung, Thomas ^a   Lam, Wynnie W M ^a   Wong, Ka Sing ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chinese; Rivastigmine; Subcortical vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ANOREXIA; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GOUT; HUMAN; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LEG CRAMP; MAINTENANCE THERAPY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NAUSEA; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STROKE; TREATMENT DURATION; TREND STUDY; URINARY TRACT INFECTION; VOMITING;

EID: 38149030045     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aharon-peretz J, Kliot D, Tomer R. 2000. Behavioral differences between white matter lacunar dementia and Alzheimer's disease: a comparison on the neuropsychiatric inventory. Dement Geriatr Cogn Disord, 11:294-8.
2. Black S, Roman GC, Geldmacher DS, et al. 2003. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 34:2323-30.
3. Bullock R. 2005. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin, 21:1-10.
4. Chiu HF, Lam LC, Chi I, et al. 1998. Prevalence of dementia in Chinese elderly in Hong Kong. Neurology, 50:1002-9.
5. Chiu HFK, Kee HC, Chung WS, et al. 1994. Reliability and validity of the Cantonese version of Mini-mental state examination - a preliminary study. Hong Kong Coll Psychiatry, 4(S2):25-8.
6. Craig D, Birks J. 2006. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev, CD004746.
7. Dubois B, Slachevsky A, Litvan I, et al. 2000. The FAB: a Frontal Assessment Battery at bedside. Neurology, 55:1621-6.
8. Erkinjuntti T, Inzitari D, Pantoni L, et al. 2000. Research criteria for subcortical vascular dementia in clinical trials. J Neurol Transm Suppl, 59:23-30.
9. Erkinjuntti T, Kurz A, Gauthier S, et al. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 359:1283-90.
10. Ferri CP, Prince M, Brayne C, et al. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet, 366:2112-7.
11. Ikeda M, Hokoishi K, Maki N, et al. 2001. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology, 57:839-44.
12. Jirong Y, Xiaoyan Y, Taixiang W, et al. 2004. Zhiling decoction for vascular dementia. Cochrane Database Syst Rev, CD004670.
13. Leung VP, Lam LC, Chiu HF, et al. 2001. Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). Int J Geriatr Psychiatry, 16:789-93.
14. Mega MS, Masterman DM, O'Connor SM, et al. 1999. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol, 56:1388-93.
15. Mok VC, Wong A, Yim P, et al. 2004. The validity and reliability of chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct. Alzheimer Dis Assoc Disord, 18:68-74.
16. Moretti R, Torre P, Antonello RM, et al. 2002. Rivastiginine in subcortical vascular dementia: an open 22-month study. J Neurol Sci, 203-204:141-6.
17. Moretti R, Torre P, Antonello RM, et al. 2003. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen, 18:265-72.
18. Morris JC. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43:2412-4.
19. Rosler M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ, 318:633-8.
20. Salloway SCS, Malloy P, Pratt RD. 2003. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. 1st Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG). Goteburg, Sweden.
21. Tang WK, Chan SS, Chiu HF, et al. 2004. Frequency and determinants of poststroke dementia in Chinese. Stroke, 35:930-5.
22. Tong A, Man D. 2002. The validation ofthe Hong Kong Chinese Version of the Lawton Instrumental Activities of Daily Living Scale for Institutionalized Elderly Persons. Occupation, Participation and Health, 22:132-41.
23. Wilkinson D, Doody R, Helme R, et al. 2003. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 61:479-86.
24. Zhang ZX, Zahner GE, Roman GC, et al. 2005. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol, 62:447-53.